IDEAYA Biosciences Inc (NASDAQ:IDYA), a United States-based oncology-focused biotechnology company, has dosed its first patient in the phase one combination study of IDE196 and binimetinib, an MEK inhibitor, intended to treat metastatic uveal melanoma (MUM), it was reported on Thursday.
The company is assessing the clinical combination of IDE196 and binimetinib, which is being provided by Pfizer based on a clinical trial collaboration and supply contract.
The company expects interim data from the MEK combination study in late 2021 to early 2022, when the firm will assess a potential registrational path for MUM and a potential collaboration.
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval